title: Functional effects of phosphoramidon and captopril on exogenous neuropeptides in human nasal mucosa.
abstract: The functional effects of the intranasal application of exogenous vasoactive intestinal polypeptide (VIP), substance P (SP) and calcitonin gene-related peptide (CGRP) were evaluated in 12 healthy volunteers before and after neutral endopeptidase (NEP) inhibition with phosphoramidon (PA) and angiotensin-converting enzyme (ACE) inhibition with captopril. The three neuropeptides increased nasal airway resistance (NAR) measured by anterior rhinomanometry and superficial capillary blood flow measured by laser Doppler flowmetry (LDF). After pretreatment of the nasal mucosa with PA, the effects of VIP, SP and CGRP on the LDF signal, NAR and mucus production were potentiated, whereas local pretreatment with captopril did not modify these functional effects. These observations suggest that NEP, but not ACE, may participate in the catabolism of neuropeptides when applied directly to the human nasal mucosa. Furthermore, since these neuropeptides induced nasal obstruction, increased blood flow and rhinorrhea, a decreased activity of the enzymes involved in their degradation could be involved in the physiopathology of rhinitis symptoms.
authors.affiliation: Department of Otorhinolaryngology, University Cantonal Hospital, Geneva, Switzerland.
authors.forename: C
authors.initials: C
authors.lastname: Châtelain
authors.forename: N
authors.initials: N
authors.lastname: Pochon
authors.forename: J S
authors.initials: JS
authors.lastname: Lacroix
mesh_terms: D000328:Adult; D000403:Airway Resistance / Q000187:drug effects; D001783:Blood Flow Velocity; D015740:Calcitonin Gene-Related Peptide / Q000494:pharmacology; D002216:Captopril / Q000494:pharmacology*; D004357:Drug Synergism; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D006020:Glycopeptides / Q000494:pharmacology*; D006801:Humans; D017078:Laser-Doppler Flowmetry; D008875:Middle Aged; D009093:Mucus / Q000187:drug effects / Q000378:metabolism; D009297:Nasal Mucosa / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D015260:Neprilysin / Q000187:drug effects* / Q000378:metabolism; D007703:Peptidyl-Dipeptidase A / Q000187:drug effects* / Q000378:metabolism; D011480:Protease Inhibitors / Q000494:pharmacology*; D013373:Substance P / Q000494:pharmacology; D013997:Time Factors; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology
chemical_list: D006020:Glycopeptides; D011480:Protease Inhibitors; D013373:Substance P; D014660:Vasoactive Intestinal Peptide; D002216:Captopril; D007703:Peptidyl-Dipeptidase A; D015260:Neprilysin; D015740:Calcitonin Gene-Related Peptide; C008890:phosphoramidon